MMP inhibition modulates TNF-alpha transgenic mouse phenotype early in the development of heart failure.

Myocardial extracellular matrix remodeling regulated by matrix metalloproteinases (MMPs) is implicated in the progression of heart failure. We hypothesized that MMP inhibition may modulate extracellular matrix remodeling and prevent the progression of heart failure. The effects of the MMP inhibitor BB-94 (also known as batimastat) on MMP expression, collagen expression, collagen deposition, collagen denaturation, and left ventricular structure and function in transgenic mice with cardiac-restricted overexpression of tumor necrosis factor-alpha (TNF-alpha) (TNF1.6) were assessed. The results showed that BB-94 reduced the expression of collagens, increased insoluble collagen and the ratio of undenatured to total soluble collagen, and prevented myocardial hypertrophy and diastolic dysfunction in young TNF1.6 mice. Furthermore, the treatment significantly improved cumulative survival of TNF1.6 mice. However, MMP inhibition did not have salutary effects on ventricular size and function in old mice with established heart failure. The results suggest that MMP activation may play a critical role in changes of myocardial function through the remodeling of extracellular matrix, and MMP inhibition may serve as a potential therapeutic strategy for heart failure, albeit within a narrow window during the development of heart failure.

[1]  S. Kovacs,et al.  Can trasmitral Doppler E-waves differentiate hypertensive hearts from normal? , 1997, Hypertension.

[2]  D. Mann,et al.  Dynamic regulation of the extracellular matrix after mechanical unloading of the failing human heart: recovering the missing link in left ventricular remodeling. , 2001, Circulation.

[3]  M. Arthur.  Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis. , 2000, American journal of physiology. Gastrointestinal and liver physiology.

[4]  S. Tyagi,et al.  Matrix metalloproteinase activity expression in infarcted, noninfarcted and dilated cardiomyopathic human hearts , 1996, Molecular and Cellular Biochemistry.

[5]  P. Birembaut,et al.  In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. , 1993, The Journal of clinical investigation.

[6]  D. Mukherjee,et al.  Alteration of collagen phenotypes in ischemic cardiomyopathy. , 1991, The Journal of clinical investigation.

[7]  M. Zile,et al.  Angiotensin-converting enzyme and matrix metalloproteinase inhibition with developing heart failure: comparative effects on left ventricular function and geometry. , 1999, The Journal of pharmacology and experimental therapeutics.

[8]  R. Bonow,et al.  Diastolic dysfunction as a cause of heart failure. , 1993, Hospital practice.

[9]  J S Janicki,et al.  Ventricular remodeling in heart failure: the role of myocardial collagen. , 1995, Advances in experimental medicine and biology.

[10]  M. Rothenberg,et al.  New drugs on the horizon: matrix metalloproteinase inhibitors. , 1998, Stem cells.

[11]  A. Feldman,et al.  Sex-related survival differences in murine cardiomyopathy are associated with differences in TNF-receptor expression. , 2000, The Journal of clinical investigation.

[12]  A. Stoppacciaro,et al.  Inhibition of the metastatic spread and growth of B16‐BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor , 1994, International journal of cancer.

[13]  J. McEwan,et al.  Matrix metalloproteinases and cardiovascular disease. , 1995, Circulation research.

[14]  A. Koretsky,et al.  Dilated Cardiomyopathy in Transgenic Mice With Cardiac-Specific Overexpression of Tumor Necrosis Factor-α , 1997 .

[15]  M. Zile,et al.  Matrix metalloproteinase inhibition during the development of congestive heart failure : effects on left ventricular dimensions and function. , 1999, Circulation research.

[16]  A. Feldman,et al.  Downregulation of Matrix Metalloproteinases and Reduction in Collagen Damage in the Failing Human Heart After Support With Left Ventricular Assist Devices , 2001, Circulation.

[17]  R. Dickson,et al.  Matrix metalloproteinase inhibitors , 1997, Investigational New Drugs.

[18]  A. Feldman,et al.  Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. , 2000, Cardiovascular research.

[19]  Simon C Watkins,et al.  Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[20]  F. Spinale,et al.  Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function. , 1998, Circulation research.

[21]  R. E. Neuman,et al.  The determination of collagen and elastin in tissues. , 1950, The Journal of biological chemistry.

[22]  K. Weber,et al.  Direct extraction and estimation of collagenase(s) activity by zymography in microquantities of rat myocardium and uterus. , 1993, Clinical biochemistry.

[23]  T. Mela,et al.  Reduction in Myocardial Collagen Cross-Linking Parallels Left Ventricular Dilatation in Rat Models of Systolic Chamber Dysfunction , 2001, Circulation.

[24]  J. K. Lee,et al.  A serine elastase inhibitor reduces inflammation and fibrosis and preserves cardiac function after experimentally-induced murine myocarditis , 1998, Nature Medicine.

[25]  H. Stegemann,et al.  Determination of hydroxyproline. , 1967, Clinica chimica acta; international journal of clinical chemistry.

[26]  A. Feldman,et al.  Proinflammatory cytokines regulate tissue inhibitors of metalloproteinases and disintegrin metalloproteinase in cardiac cells. , 1999, Cardiovascular research.

[27]  E. Vuorio,et al.  Specific hybridization probes for mouse type I, II, III and IX collagen mRNAs. , 1991, Biochimica et biophysica acta.

[28]  A. Rosemurgy,et al.  Matrix metalloproteinase (MMP) inhibition selectively decreases type II MMP activity in a murine model of pancreatic cancer. , 1999, The Journal of surgical research.

[29]  Y. Sun,et al.  Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. , 1998, Circulation.

[30]  E. J. Miller,et al.  Preparation and characterization of the different types of collagen. , 1982, Methods in enzymology.

[31]  F. Spinale,et al.  Increased Matrix Metalloproteinase Activity and Selective Upregulation in LV Myocardium From Patients With End-Stage Dilated Cardiomyopathy , 1998 .

[32]  P. Brown.  Synthetic Inhibitors of Matrix Metalloproteinases , 1998 .

[33]  P. Libby,et al.  Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. , 1999, Circulation.

[34]  Z. Galis,et al.  Myocardial matrix metalloproteinase activity and abundance with congestive heart failure. , 1998, American journal of physiology. Heart and circulatory physiology.

[35]  T. Bocan,et al.  MMP/TIMP expression in spontaneously hypertensive heart failure rats: the effect of ACE- and MMP-inhibition. , 2000, Cardiovascular research.

[36]  R. Hoffman,et al.  Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. , 1994, Cancer research.

[37]  Jussi Taipale,et al.  Growth factors in the extracellular matrix , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[38]  Stanton A. Glantz,et al.  Primer of biostatistics : statistical software program version 6.0 , 1981 .